Cardiovascular management of septic shock.

This review will cover septic shock as a manifestation of severe sepsis. The reader is referred to other articles, which review the myriad multisystem dysfunctions associated with severe sepsis (1– 4), and is reminded that as in all patients with sepsis early initiation of appropriate antibiotics and adequate source control are key components of septic shock treatment. Ascertaining the incidence of septic shock is limited by the variability in definitions used in epidemiologic studies, the analysis of septic shock as a subset of patients with severe sepsis, and shortcomings of methods used to calculate the incidence of severe sepsis. In five recent large clinical trials that enrolled a total of 5,461 patients with severe sepsis (criteria evidence of infection, systemic inflammatory response syndrome, and at least one organ dysfunction/hypoperfusion), the incidence of septic shock ranged from 52% to 71% of patients with severe sepsis, with a mean of 58% (5–9). A recent study used International Classification of Diseases (ICD)-9 hospital diagnostic codes for infection and acute organ dysfunction to estimate 751,000 cases of severe sepsis per annum in the United States (10). Taking the incidence of septic shock in severe sepsis from the five studies above, septic shock would, therefore, be predicted to occur annually in 435,580 patients in the United States. The mortality of septic shock can be estimated more reliably. Table 1 shows a compilation of septic shock mortalities drawn from the placebo arms of clinical trials (8, 9, 11–22). Figure 1 shows improvement in septic shock mortality over time (23). Historical Perspective The word sepsis is derived from the Greek language (24). Pepsis was good, embodying the natural processes of maturation and fermentation. Sepsis, however, was bad and synonymous with putrefaction as characterized by bad smell. It was thousands of years later before Pasteur conclusively linked putrefaction to a bacterial cause. The word shock has its derivation from the French root “choquer,” meaning “to collide with.” Based on our current understanding of the pathophysiology of septic shock, the collision of the body’s defenses with the invading organism, this seems to be particularly appropriate terminology.

[1]  D. Cook,et al.  Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. , 1995, Critical care medicine.

[2]  H P Greisler,et al.  Noninvasive cardiac monitoring. , 1987, The Nursing clinics of North America.

[3]  W. Schumer Steroids in the Treatment of Clinical Septic Shock , 1976, Annals of surgery.

[4]  P. Bollaert,et al.  Reversal of late septic shock with supraphysiologic doses of hydrocortisone. , 1998, Critical care medicine.

[5]  J. Cohen Practical implications of the availability of effective drugs to treat sepsis. , 2001, Current opinion in critical care.

[6]  G. Schierhout,et al.  Fluid resuscitation with colloid or crystalloid solutions in critically ill patients: a systematic review of randomised trials , 1998, BMJ.

[7]  G. Majno The ancient riddle of sigma eta psi iota sigma (sepsis). , 1991, The Journal of infectious diseases.

[8]  G. Schmidt,et al.  Sodium bicarbonate for the treatment of lactic acidosis. , 2000, Chest.

[9]  M. Haller,et al.  Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. , 1999, Critical care medicine.

[10]  J. Siegel,et al.  Arteriovenous shunting in high cardiac output shcok syndromes. , 1968, Surgery, gynecology & obstetrics.

[11]  C. Sprung,et al.  The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. , 1984, The New England journal of medicine.

[12]  L. Papazian,et al.  Norepinephrine or dopamine for the treatment of hyperdynamic septic shock? , 1992, Chest.

[13]  J. Takala,et al.  Regional blood flow and oxygen transport in septic shock , 1993, Critical care medicine.

[14]  R. Bellomo,et al.  A phase II randomized, controlled trial of continuous hemofiltration in sepsis , 2002, Critical care medicine.

[15]  L. Goldman,et al.  The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators. , 1996, JAMA.

[16]  D. Kuhl Current strategies for managing the patient with sepsis. , 2002, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[17]  E. Ivers,et al.  Early Goal-Directed Therapy in the Treatment of Severe Sepsis and Septic Shock , 2001 .

[18]  D. Landry,et al.  The pathogenesis of vasodilatory shock. , 2001, The New England journal of medicine.

[19]  M. Oz,et al.  A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. , 1997, Circulation.

[20]  S. Opal,et al.  Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. , 1997, Critical care medicine.

[21]  F Baisch,et al.  Noninvasive cardiac output measurement by arterial pulse analysis compared with inert gas rebreathing. , 1993, Journal of applied physiology.

[22]  B. Wiggs,et al.  Bicarbonate does not improve hemodynamics in critically ill patients who have lactic acidosis. A prospective, controlled clinical study. , 1990, Annals of internal medicine.

[23]  M. Weil,et al.  SHOCK CAUSED BY GRAM-NEGATIVE MICROORGANISMS. ANALYSIS OF 169 CASES. , 1964, Annals of internal medicine.

[24]  C. Sessler,et al.  New concepts in sepsis , 2002, Current opinion in critical care.

[25]  G. Clermont,et al.  Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care , 2001, Critical care medicine.

[26]  R. Bellomo,et al.  Pro/con clinical debate: Is high-volume hemofiltration beneficial in the treatment of septic shock? , 2002, Critical care.

[27]  L. Lasagna,et al.  The effect of hydrocortisone upon the course of pneumococcal pneumonia treated with penicillin. , 1956, Bulletin of the Johns Hopkins Hospital.

[28]  E. Rivers,et al.  Early goal-directed therapy prevents organ failure and mortality in severe sepsis and septic shock , 2003 .

[29]  M. Welte,et al.  N-acetylcysteine increases liver blood flow and improves liver function in septic shock patients: Results of a prospective, randomized, double-blind study , 2000, Critical care medicine.

[30]  J. Vincent,et al.  Has the mortality of septic shock changed with time. , 1998, Critical care medicine.

[31]  K. Laupland,et al.  Utility of esophageal Doppler as a minimally invasive hemodynamic monitor: a review , 2002, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[32]  A. Wu Increased troponin in patients with sepsis and septic shock: myocardial necrosis or reversible myocardial depression? , 2001, Intensive Care Medicine.

[33]  E. Bennett,et al.  A randomized clinical trial of the effect of deliberate perioperative increase of oxygen delivery on mortality in high-risk surgical patients. , 1993, JAMA.

[34]  P. Nabet,et al.  Comparison of norepinephrine and dobutamine to epinephrine for hemodynamics, lactate metabolism, and gastric tonometric variables in septic shock: a prospective, randomized study , 1997, Intensive Care Medicine.

[35]  J. Siegel Assessing the use of activated protein C in the treatment of severe sepsis. , 2002, The New England journal of medicine.

[36]  G. Guyatt,et al.  Colloid Use for Fluid Resuscitation: Evidence and Spin , 2001, Annals of Internal Medicine.

[37]  R. Lyons The effects of high-dose corticosteroids in patients with septic shock , 1985 .

[38]  C. Perret,et al.  Pulmonary artery catheter: does the problem lie in the users? , 2002, Chest.

[39]  R. Nunnally,et al.  Carbicarb, sodium bicarbonate, and sodium chloride in hypoxic lactic acidosis. Effect on arterial blood gases, lactate concentrations, hemodynamic variables, and myocardial intracellular pH. , 1993, Chest.

[40]  J. Morris,et al.  Adrenal hemorrhage: a 25-year experience at the Mayo Clinic. , 2001, Mayo Clinic proceedings.

[41]  Hypercarbic acidosis reduces cardiac resuscitability , 1991, Critical care medicine.

[42]  R. C. Dennis,et al.  Myocardial depression during sepsis. , 1977, American journal of surgery.

[43]  J. Bakker,et al.  Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock* , 2004, Critical care medicine.

[44]  D. Mathieu,et al.  Effects of bicarbonate therapy on hemodynamics and tissue oxygenation in patients with lactic acidosis: A prospective, controlled clinical study , 1991, Critical care medicine.

[45]  R. Postier,et al.  Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: A multicenter, randomized, placebo-controlled, single-blind, dose escalation study , 2001, Critical care medicine.

[46]  F. Kern,et al.  Massive elevation of procalcitonin plasma levels in the absence of infection in kidney transplant patients treated with pan-T-cell antibodies , 2001, Intensive Care Medicine.

[47]  J. Shapiro Functional and metabolic responses of isolated hearts to acidosis: effects of sodium bicarbonate and Carbicarb. , 1990, The American journal of physiology.

[48]  S. Pastores,et al.  Splanchnic ischemia and gut mucosal injury in sepsis and the multiple organ dysfunction syndrome. , 1996, The American journal of gastroenterology.

[49]  S. Nasraway,et al.  Normal lactate/pyruvate ratio during overwhelming polymicrobial bacteremia and multiple organ failure. , 1994, Anesthesiology.

[50]  Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock , 2003, Current infectious disease reports.

[51]  Richard F. Davis,et al.  "Normothermic range" temperature affects myocardial infarct size. , 1994, Cardiovascular research.

[52]  K. Walley,et al.  Physiology of vasopressin relevant to management of septic shock. , 2001, Chest.

[53]  N. Maassen,et al.  Evaluation of noninvasive determinants for capillary leakage syndrome in septic shock patients , 2000, Intensive Care Medicine.

[54]  R. Dellinger Current therapy for sepsis. , 1999, Infectious disease clinics of North America.

[55]  J. A. Kruse,et al.  E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators. , 2000, JAMA.

[56]  G. Camussi,et al.  Hemofiltration reduces the serum priming activity on neutrophil chemiluminescence in septic patients. , 2001, Kidney international.

[57]  D. Frommer The effects of high-dose corticosteroids in patients with septic shock: Sprung CL, Caralis PV, Marcial EH, et al N Engl J Med 311:1137–1143 Nov 1984 , 1985 .

[58]  L. Kinsell,et al.  THE USE OF CORTICOIDS IN ASSOCIATION WITH ANTIBIOTICS IN THE MANAGEMENT OF UNUSUALLY SEVERE INFECTIONS , 1955, Annals of the New York Academy of Sciences.

[59]  M. Weil,et al.  The Shock Syndrome Associated with Bacteremia Due to Gram-Negative Bacilli , 1958 .

[60]  G. Meduri An Historical Review of Glucocorticoid Treatment in Sepsis. Disease Pathophysiology and the Design of Treatment Investigation , 1999 .

[61]  M. Fink Cytopathic hypoxia. Is oxygen use impaired in sepsis as a result of an acquired intrinsic derangement in cellular respiration? , 2002, Critical care clinics.

[62]  J. Hibbert,et al.  Lactic acidosis during sepsis is related to increased pyruvate production, not deficits in tissue oxygen availability. , 1996, Annals of surgery.

[63]  L. U. G. Attinoni,et al.  A TRIAL OF GOAL-ORIENTED HEMODYNAMIC THERAPY IN CRITICALLY ILL PATIENTS , 2000 .

[64]  A. Groeneveld,et al.  Peripheral vascular resistance in septic shock: its relation to outcome , 2004, Intensive Care Medicine.

[65]  J. W. Henry,et al.  Fever in acute pulmonary embolism. , 2000, Chest.

[66]  X Viviand,et al.  Effect of norepinephrine on the outcome of septic shock , 2000, Critical care medicine.

[67]  Rinaldo Bellomo,et al.  A pilot study of coupled plasma filtration with adsorption in septic shock* , 2002, Critical care medicine.

[68]  K. Demirel,et al.  Fever in pulmonary embolism , 2005, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[69]  M. C. Townsend,et al.  Experience with phenylephrine as a component of the pharmacologie support of septic shock , 1991, Critical care medicine.

[70]  D. Pittet,et al.  Impact of immunomodulating therapy on morbidity in patients with severe sepsis. , 1999, American journal of respiratory and critical care medicine.

[71]  F. Gouin,et al.  Renal effects of norepinephrine used to treat septic shock patients. , 1990, Critical care medicine.

[72]  W. Knaus,et al.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. , 1992, Chest.

[73]  G. Majno,et al.  The ancient riddle of σηψιζ (sepsis) , 1991 .

[74]  P. Crone,et al.  Effect of maximizing oxygen delivery on morbidity and mortality rates in critically ill patients: a prospective, randomized, controlled study. , 1994, Critical care medicine.

[75]  R. Alcázar,et al.  Silent transmural myocardial ischemia during septic shock in a patient with normal coronary arteries , 2001, Intensive Care Medicine.

[76]  R. Bellomo,et al.  High-volume haemofiltration in human septic shock , 2001, Intensive Care Medicine.

[77]  K. Werdan,et al.  Intravenous immunoglobulin for prophylaxis and therapy of sepsis. , 2001, Current opinion in critical care.

[78]  W. Shoemaker,et al.  Prospective trial of supranormal values of survivors as therapeutic goals in high-risk surgical patients. , 1988, Chest.

[79]  A. Wechsler-Fördös,et al.  The effects of norepinephrine on hemodynamics and renal function in severe septic shock states , 2005, Intensive Care Medicine.

[80]  M. Oz,et al.  Reversal by vasopressin of intractable hypotension in the late phase of hemorrhagic shock. , 1999, Circulation.

[81]  R. Townsend,et al.  Low-dose vasopressin in the treatment of vasodilatory septic shock. , 1999, The Journal of trauma.

[82]  R. Wenzel Treating sepsis. , 2002, The New England journal of medicine.

[83]  Cam Donaldson,et al.  An economic evaluation of activated protein C treatment for severe sepsis. , 2002, The New England journal of medicine.

[84]  M. Pinaud,et al.  Norepinephrine therapy has no deleterious renal effects in human septic shock. , 1989, Critical care medicine.

[85]  B. Altura Dose-response relationships for arginine vasopressin and synthetic analogs on three types of rat blood vessels: possible evidence for regional differences in vasopressin receptor sites within a mammal. , 1975, The Journal of pharmacology and experimental therapeutics.

[86]  M. Haupt,et al.  Impact of critical care physician staffing on patients with septic shock in a university hospital medical intensive care unit. , 1988, JAMA.

[87]  S. Opal,et al.  High-Dose Antithrombin III in Severe Sepsis: A Randomized Controlled Trial , 2001 .

[88]  S. Berger,et al.  Clinical trial design in studies of corticosteroids for bacterial infections. , 1974, Annals of internal medicine.

[89]  J P Archie,et al.  Mathematic Coupling of Data: A Common Source of Error , 1981, Annals of surgery.

[90]  C. Esmon,et al.  Dysfunction of endothelial protein C activation in severe meningococcal sepsis. , 2001, The New England journal of medicine.

[91]  E. Rackow,et al.  Elevation of cardiac output and oxygen delivery improves outcome in septic shock. , 1992, Chest.

[92]  J. Edwards,et al.  Reversal of intractable septic shock with norepinephrine therapy. , 1988, Critical care medicine.

[93]  J. E. Cassidy Therapy in collapse due to meningococcus infection. , 1957, Annals of internal medicine.

[94]  M. Weil,et al.  HEMODYNAMIC AND METABOLIC STUDIES ON SHOCK ASSOCIATED WITH GRAM NEGATIVE BACTEREMIA , 1973, Medicine.

[95]  R. Bersin,et al.  A Controlled Clinical Trial of Dichloroacetate for Treatment of Lactic Acidosis in Adults , 1992 .

[96]  F. Ognibene,et al.  Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. , 1990, Annals of internal medicine.

[97]  T. Butler,et al.  Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients , 2001, Critical care medicine.

[98]  A. Jensen,et al.  Treatment and outcome of Staphylococcus aureus bacteremia: a prospective study of 278 cases. , 2002, Archives of internal medicine.

[99]  J. Vincent,et al.  Practice parameters for hemodynamic support of sepsis in adult patients in sepsis. Task Force of the American College of Critical Care Medicine, Society of Critical Care Medicine. , 1999, Critical care medicine.

[100]  A. Weyland,et al.  Comparison of cardiac output assessed by pulse-contour analysis and thermodilution in patients undergoing minimally invasive direct coronary artery bypass grafting. , 1999, Journal of cardiothoracic and vascular anesthesia.

[101]  Véronique Sébille,et al.  Effect of Treatment With Low Doses of Hydrocortisone and Fludrocortisone on Mortality in Patients With Septic Shock , 2002 .

[102]  T. Clemmer,et al.  A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. , 1987, The New England journal of medicine.

[103]  M. Fink,et al.  Cytopathic Hypoxia in Sepsis: An Overview , 1999 .

[104]  P. Marik,et al.  The hemodynamic derangements in sepsis: implications for treatment strategies. , 1998, Chest.

[105]  M. Dünser,et al.  The Effects of Vasopressin on Systemic Hemodynamics in Catecholamine-Resistant Septic and Postcardiotomy Shock: A Retrospective Analysis , 2001, Anesthesia and analgesia.

[106]  G. Van den Berghe,et al.  Anterior pituitary function during critical illness and dopamine treatment. , 1996, Critical care medicine.

[107]  I. Mackenzie The haemodynamics of human septic shock * , 2001, Anaesthesia.

[108]  B. Stegmayr,et al.  Plasmapheresis in severe sepsis or septic shock. , 1996, Blood purification.

[109]  J. De Sutter,et al.  Cytokine removal during continuous hemofiltration in septic patients. , 1999, Journal of the American Society of Nephrology : JASN.

[110]  R. Dellinger,et al.  Pharmacologic issues in the management of septic shock. , 2000, Critical care clinics.

[111]  H. S. Warren,et al.  Risks and benefits of activated protein C treatment for severe sepsis. , 2002, The New England journal of medicine.

[112]  R. Hotchkiss,et al.  Reevaluation of the role of cellular hypoxia and bioenergetic failure in sepsis. , 1992, JAMA.

[113]  P. Marik,et al.  Adrenal insufficiency in the critically ill: a new look at an old problem. , 2002, Chest.

[114]  S. Kleinman,et al.  A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care , 1999 .

[115]  R. Lefering,et al.  Steroid controversy in sepsis and septic shock: a meta-analysis. , 1995, Critical care medicine.

[116]  G. Gallioli,et al.  Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. , 1998, Intensive care medicine.

[117]  A. Feydy,et al.  Depletion of neurohypophyseal content of vasopressin in septic shock. , 2002, Critical care medicine.

[118]  K. Reinhart,et al.  Comparison of dopamine to dobutamine and norepinephrine for oxygen delivery and uptake in septic shock. , 1995, Critical care medicine.

[119]  D. Cook,et al.  Crystalloids vs. colloids in fluid resuscitation: a systematic review. , 1999, Critical care medicine.

[120]  T. Fehr,et al.  Elevation of troponin I in sepsis and septic shock , 2001, Intensive Care Medicine.

[121]  J. Shelhamer,et al.  Profound but reversible myocardial depression in patients with septic shock. , 1984, Annals of internal medicine.

[122]  John C. Chaney,et al.  Minimally invasive hemodynamic monitoring for the intensivist: Current and emerging technology , 2002, Critical care medicine.

[123]  M. Llewelyn,et al.  New insights into the pathogenesis and therapy of sepsis and septic shock. , 2001, Current clinical topics in infectious diseases.

[124]  D. Annane,et al.  A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. , 2000, JAMA.

[125]  J. Vincent,et al.  Early hemodynamic course of septic shock. , 1995, Critical care medicine.

[126]  J. Vincent,et al.  Myocardial depression characterizes the fatal course of septic shock. , 1992, Surgery.

[127]  William A. Knaus,et al.  The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators. , 1996, Journal of the American Medical Association (JAMA).

[128]  R. Busund,et al.  Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial , 2002, Intensive Care Medicine.

[129]  C. Hinds,et al.  Elevation of systemic oxygen delivery in the treatment of critically ill patients. , 1994, The New England journal of medicine.

[130]  W. Shoemaker,et al.  Sequence of physiologic patterns in surgical septic shock , 1993, Critical care medicine.

[131]  L. Goldman,et al.  The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators. , 1996, JAMA.

[132]  T. Nakanishi,et al.  Influence of acidosis on inotropic effect of catecholamines in newborn rabbit hearts. , 1987, The American journal of physiology.

[133]  C. Chopin,et al.  Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. , 1993, Chest.

[134]  D. Berman,et al.  Left ventricular performance in septic shock: reversible segmental and global abnormalities. , 1985, American heart journal.

[135]  I. Reid,et al.  Role of vasopressin deficiency in the vasodilation of septic shock. , 1997, Circulation.

[136]  M. Haupt,et al.  Fluid resuscitation in circulatory shock: a comparison of the cardiorespiratory effects of albumin, hetastarch, and saline solutions in patients with hypovolemic and septic shock. , 1983, Critical care medicine.

[137]  Cornelius Weiller,et al.  Dysfunction of vasomotor reactivity in severe sepsis and septic shock , 2001, Intensive Care Medicine.

[138]  S. Nasraway,et al.  Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock , 1998, The Lancet.

[139]  Maximilians-Universitat Munchen Stress doses of hydrocortisone reverse hyperdynamic septic shock: A prospective, randomized, double-blind, single-center study , 2005 .

[140]  T. Evans,et al.  EMERGING THERAPIES IN SEVERE SEPSIS , 2002, Thorax.

[141]  E. Rackow,et al.  Effects of perfusion pressure on tissue perfusion in septic shock , 2000, Critical care medicine.

[142]  Yoshiki Mori,et al.  A validation study of aortic stroke volume using dynamic 4-dimensional color Doppler: an in vivo study. , 2002, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[143]  P. Poole‐Wilson,et al.  Effect of pH on ionic exchange and function in rat and rabbit myocardium. , 1975, The American journal of physiology.

[144]  C. Ince,et al.  Microcirculatory oxygenation and shunting in sepsis and shock. , 1999, Critical care medicine.

[145]  J Ean,et al.  Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.